Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) - Net Assets

Latest as of September 2025: CN¥1.62 Billion CNY ≈ $236.85 Million USD

Based on the latest financial reports, Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) has net assets worth CN¥1.62 Billion CNY (≈ $236.85 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.13 Billion ≈ $311.96 Million USD) and total liabilities (CN¥513.25 Million ≈ $75.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥1.62 Billion
% of Total Assets 75.92%
Annual Growth Rate 19.37%
5-Year Change 21.71%
10-Year Change 78.29%
Growth Volatility 33.03

Zhejiang Shapuaisi Pharmaceutical Co Ltd - Net Assets Trend (2008–2024)

This chart illustrates how Zhejiang Shapuaisi Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Zhejiang Shapuaisi Pharmaceutical Co Ltd balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Zhejiang Shapuaisi Pharmaceutical Co Ltd (2008–2024)

The table below shows the annual net assets of Zhejiang Shapuaisi Pharmaceutical Co Ltd from 2008 to 2024. For live valuation and market cap data, see market value of Zhejiang Shapuaisi Pharmaceutical Co Ltd.

Year Net Assets Change
2024-12-31 CN¥1.59 Billion
≈ $232.62 Million
-8.08%
2023-12-31 CN¥1.73 Billion
≈ $253.06 Million
+0.74%
2022-12-31 CN¥1.72 Billion
≈ $251.20 Million
+26.93%
2021-12-31 CN¥1.35 Billion
≈ $197.91 Million
+3.55%
2020-12-31 CN¥1.31 Billion
≈ $191.13 Million
-12.28%
2019-12-31 CN¥1.49 Billion
≈ $217.89 Million
+0.53%
2018-12-31 CN¥1.48 Billion
≈ $216.74 Million
-10.63%
2017-12-31 CN¥1.66 Billion
≈ $242.51 Million
+3.95%
2016-12-31 CN¥1.59 Billion
≈ $233.29 Million
+78.80%
2015-12-31 CN¥891.62 Million
≈ $130.47 Million
+16.87%
2014-12-31 CN¥762.90 Million
≈ $111.64 Million
+115.93%
2013-12-31 CN¥353.31 Million
≈ $51.70 Million
+28.84%
2012-12-31 CN¥274.21 Million
≈ $40.13 Million
+35.78%
2011-12-31 CN¥201.95 Million
≈ $29.55 Million
+32.83%
2010-12-31 CN¥152.04 Million
≈ $22.25 Million
+38.63%
2009-12-31 CN¥109.67 Million
≈ $16.05 Million
+17.19%
2008-12-31 CN¥93.58 Million
≈ $13.69 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang Shapuaisi Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 7195.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥211.97 Million 13.33%
Common Stock CN¥375.93 Million 23.65%
Other Components CN¥1.00 Billion 63.02%
Total Equity CN¥1.59 Billion 100.00%

Zhejiang Shapuaisi Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang Shapuaisi Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Lycopodium Ltd
AU:LYL
$365.82 Million
Hong Tai Electric Industrial Co Ltd
TW:1612
$365.97 Million
Berjaya Corporation Bhd
KLSE:3395
$366.06 Million
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
$366.36 Million
Hai An Transport and Stevedoring JSC
VN:HAH
$365.69 Million
Zhejiang Giuseppe Garment Co Ltd
SHE:002687
$365.63 Million
ATN International Inc
NASDAQ:ATNI
$365.41 Million
Agro Tech Foods Limited
NSE:ATFL
$365.36 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang Shapuaisi Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,719,676,896 to 1,589,629,316, a change of -130,047,580 (-7.6%).
  • Net loss of 123,442,602 reduced equity.
  • Dividend payments of 14,527,633 reduced retained earnings.
  • Share repurchases of 13,672,958 reduced equity.
  • Other factors increased equity by 21,595,613.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-123.44 Million -7.77%
Dividends Paid CN¥14.53 Million -0.91%
Share Repurchases CN¥13.67 Million -0.86%
Other Changes CN¥21.60 Million +1.36%
Total Change CN¥- -7.56%

Book Value vs Market Value Analysis

This analysis compares Zhejiang Shapuaisi Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.57x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 15.85x to 1.57x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2008-12-31 CN¥0.42 CN¥6.68 x
2009-12-31 CN¥0.49 CN¥6.68 x
2010-12-31 CN¥0.68 CN¥6.68 x
2011-12-31 CN¥0.91 CN¥6.68 x
2012-12-31 CN¥1.23 CN¥6.68 x
2013-12-31 CN¥1.58 CN¥6.68 x
2014-12-31 CN¥2.94 CN¥6.68 x
2015-12-31 CN¥3.01 CN¥6.68 x
2016-12-31 CN¥5.38 CN¥6.68 x
2017-12-31 CN¥5.10 CN¥6.68 x
2018-12-31 CN¥4.57 CN¥6.68 x
2019-12-31 CN¥4.62 CN¥6.68 x
2020-12-31 CN¥4.05 CN¥6.68 x
2021-12-31 CN¥4.19 CN¥6.68 x
2022-12-31 CN¥5.20 CN¥6.68 x
2023-12-31 CN¥4.74 CN¥6.68 x
2024-12-31 CN¥4.25 CN¥6.68 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang Shapuaisi Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -7.77%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -25.51%
  • • Asset Turnover: 0.23x
  • • Equity Multiplier: 1.32x
  • Recent ROE (-7.77%) is below the historical average (11.86%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2008 19.29% 12.32% 0.90x 1.74x CN¥8.70 Million
2009 17.40% 10.93% 0.93x 1.70x CN¥8.12 Million
2010 28.35% 15.81% 1.23x 1.46x CN¥27.89 Million
2011 33.63% 16.62% 1.25x 1.62x CN¥47.72 Million
2012 33.14% 16.68% 1.05x 1.88x CN¥63.46 Million
2013 29.46% 16.57% 1.05x 1.69x CN¥68.75 Million
2014 17.21% 17.15% 0.88x 1.14x CN¥54.98 Million
2015 19.74% 19.10% 0.72x 1.43x CN¥86.87 Million
2016 17.29% 28.17% 0.53x 1.16x CN¥116.29 Million
2017 8.83% 15.59% 0.50x 1.13x CN¥-19.37 Million
2018 -8.54% -20.82% 0.37x 1.11x CN¥-274.59 Million
2019 0.53% 1.52% 0.32x 1.07x CN¥-141.05 Million
2020 -13.73% -50.07% 0.21x 1.28x CN¥-309.98 Million
2021 2.64% 5.66% 0.40x 1.17x CN¥-99.59 Million
2022 2.62% 8.14% 0.28x 1.15x CN¥-125.92 Million
2023 1.48% 3.94% 0.30x 1.26x CN¥-146.56 Million
2024 -7.77% -25.51% 0.23x 1.32x CN¥-282.41 Million

Industry Comparison

This section compares Zhejiang Shapuaisi Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $4,691,234,838
  • Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) CN¥1.62 Billion 19.29% 0.32x $365.71 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $903.62 Million 4.28% 2.45x $1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.22 Billion 5.35% 1.27x $441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $9.87 Billion 20.71% 0.25x $5.01 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.80 Billion
Wedge Industrial Co Ltd (000534) $1.15 Billion 11.42% 1.59x $3.04 Billion
Yunnan Baiyao Group Co Ltd (000538) $9.03 Billion 25.71% 0.43x $13.75 Billion
Hainan Haiyao Co Ltd (000566) $275.57 Million 17.28% 1.12x $947.33 Million
Tus Pharmaceutical Group Co Ltd (000590) $231.22 Million -38.13% 1.23x $389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597) $4.29 Billion 2.31% 2.07x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $18.87 Billion 8.83% 0.08x $3.32 Billion

About Zhejiang Shapuaisi Pharmaceutical Co Ltd

SHG:603168 China Drug Manufacturers - Specialty & Generic
Market Cap
$365.71 Million
CN¥2.50 Billion CNY
Market Cap Rank
#14152 Global
#4437 in China
Share Price
CN¥6.68
Change (1 day)
-0.89%
52-Week Range
CN¥6.29 - CN¥8.67
All Time High
CN¥31.28
About

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. Zhejiang Shapuaisi… Read more